Leonardo Teixeira is a co-founder of Endpoint Health, a precision medicine startup focused on intensive care. Dr. Teixeira received his BS and MS from Universidade Federal de Vicosa in Brazil and his PhD from Cornell University. Dr. Teixeira co-founded GeneWEAVE Biosciences, an IVD company aimed at creating diagnostic systems that rapidly detect and guide antibiotic selection for serious infections. GeneWEAVE raised a total of $25M and was acquired by Roche Diagnostics in 2015 in a deal valued at $425M USD. Additionally, Dr. Teixeira successfully won and managed several large technical contracts with large companies in Brazil, including three of the top five largest organizations. The management of these contracts included outsourcing technical and engineering expertise to help solve operational and technical improvement challenges.

Dr. Teixeira then became a research director at Roche, where he helped develop a next-generation platform from GeneWEAVE biosciences. To recognize his impact at Roche, Dr. Teixeira and his team won the Innovation Henry Erlich Scientific Excellence Runner-Up Award. Now, as a co-founder and COO of Endpoint Health, Dr. Teixeira focuses on targeted therapies for patients with critical  illnesses including sepsis and acute respiratory distress syndrome (ARDS).